Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2011-01-11
2011-01-11
Kemmerer, Elizabeth C. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S350000, C530S387100, C530S387900
Reexamination Certificate
active
07868134
ABSTRACT:
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4376110 (1983-03-01), Davis et al.
patent: 4411993 (1983-10-01), Gillis
patent: 4427115 (1984-01-01), Laipply
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: RE32011 (1985-10-01), Zimmerman et al.
patent: 4837440 (1989-06-01), Burtscher et al.
patent: 4902614 (1990-02-01), Wakabayashi et al.
patent: 5070108 (1991-12-01), Margolis
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5453492 (1995-09-01), Butzow et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5552157 (1996-09-01), Yagi et al.
patent: 5565213 (1996-10-01), Nakamori et al.
patent: 5567434 (1996-10-01), Szoka, Jr.
patent: 5627052 (1997-05-01), Schrader et al.
patent: 5641515 (1997-06-01), Ramtoola et al.
patent: 5698426 (1997-12-01), Huse
patent: 5738868 (1998-04-01), Shinkarenko et al.
patent: 5780263 (1998-07-01), Hastings et al.
patent: 5795587 (1998-08-01), Gao et al.
patent: 5811238 (1998-09-01), Stemmer et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6054561 (2000-04-01), Ring
patent: 6057421 (2000-05-01), Muller et al.
patent: 6117911 (2000-09-01), Grainger et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6703199 (2004-03-01), Koide
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 6806055 (2004-10-01), Berman et al.
patent: 6815201 (2004-11-01), Pinter
patent: 6818748 (2004-11-01), Fulton et al.
patent: 7192583 (2007-03-01), Brunkow et al.
patent: 7226902 (2007-06-01), Winkler et al.
patent: 7381409 (2008-06-01), Winkler et al.
patent: 7578999 (2009-08-01), Winkler et al.
patent: 2003/0165410 (2003-09-01), Taylor
patent: 2003/0186915 (2003-10-01), Pan et al.
patent: 2003/0229041 (2003-12-01), Sutherland et al.
patent: 2004/0009535 (2004-01-01), Brunkow et al.
patent: 2004/0023356 (2004-02-01), Krumlauf et al.
patent: 2004/0058321 (2004-03-01), Brunkow et al.
patent: 2004/0146888 (2004-07-01), Paszty et al.
patent: 2004/0158045 (2004-08-01), Brunkow et al.
patent: 2005/0014650 (2005-01-01), Seitz et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2006/0233801 (2006-10-01), Brunkow et al.
patent: 2007/0072797 (2007-03-01), Robinson et al.
patent: 2007/0110747 (2007-05-01), Paszty et al.
patent: 2007/0292444 (2007-12-01), Krumlauf et al.
patent: 2008/0182788 (2008-07-01), Brunkow et al.
patent: 2008/0234219 (2008-09-01), Brunkow et al.
patent: 2009/0074763 (2009-03-01), Padhi et al.
patent: 4-141095 (1992-05-01), None
patent: WO-91/13152 (1991-09-01), None
patent: WO-92/02551 (1992-02-01), None
patent: WO-92/06693 (1992-04-01), None
patent: WO-95/30003 (1995-11-01), None
patent: WO-98/21335 (1998-05-01), None
patent: WO-99/03996 (1999-01-01), None
patent: WO-99/06554 (1999-02-01), None
patent: WO-99/15556 (1999-04-01), None
patent: WO-00/32773 (2000-06-01), None
patent: WO-00/75317 (2000-12-01), None
patent: WO-01/64885 (2001-09-01), None
patent: WO-01/92308 (2001-12-01), None
patent: WO-01/98491 (2001-12-01), None
patent: WO-2004/098491 (2001-12-01), None
patent: WO-02/24888 (2002-03-01), None
patent: WO-03/050513 (2003-06-01), None
patent: WO-03/087763 (2003-10-01), None
patent: WO-03/106657 (2003-12-01), None
patent: WO-2004/082608 (2004-09-01), None
patent: WO-2005/003158 (2005-01-01), None
patent: WO-2005/014650 (2005-02-01), None
patent: WO-2006/102070 (2006-09-01), None
patent: WO-2006/119062 (2006-11-01), None
patent: WO-2006/119107 (2006-11-01), None
patent: WO-2008/061013 (2008-05-01), None
patent: WO-2008/115732 (2008-09-01), None
patent: WO-2008/133722 (2008-11-01), None
patent: WO-2009/039175 (2009-03-01), None
Alting-Mees et al., Monclonal antibody expression libraries: A rapid alternative to hybridomas.Strategies in Molecular Biology, 3: 1-9 (1990).
Campbell et al., Totipotency or multipotentiality of cultured cells: Applications and progress.Theriogenology, 47: 63-72 (1997).
Warmington et al., Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss.J. Bone Min. Res. 20: S22 (2005).
Albertsen et al., A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.Nature Genet. 7:472-479 (1994).
Alves et al., Sclerosteosis: A marker of Dutch ancestry?Rev. Bras. Genet. 4: 825-34 (1982).
Angal et al., A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.Mol. Immunol. 30(1):105-108 (1993).
Anonymous, Amgen presents denosumab and sclerostin antibody data at American Society for Bone and Mineral Research Annual Meeting. Amgen Media Press Release. <www.amgen.com/media/media—pr—detail.jsp?releaseID=907028> (2006).
Anonymous, UCB on track. UCB News <http://hugin.info/133973/R/1176122/233395.pdf> (2007).
Avsian-Kretchmer et al., Comparative genomic analysis of the eight-membered ring cysteine knot-containing bone morphogenetic protein antagonists.Mol. Endocrinol. 18: 1-12 (2004).
Babcook et al., A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.Proc. Natl. Acad. Sci. (USA), 93:7843-7848 (1996).
Baines et al., Purification of Immunoglobulin G (IgG), Methods in Molecular Biology. The Humana Press, Inc. vol. 10, Chapter 8, pp. 79-104 (1992).
Balemans et al., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).Hum. Mol. Genet. 10: 537-43 (2001).
Balemans et al., Localization of the Gene for Sclerosteosis to the van Buchem Disease-Gene Region on Chromosome 17q12-q21.Am. J. Hum. Genet., 64:1661-9 (1999).
Balint et al., Antibody engineering by parsimonious mutagenesis.Gene. 137: 109-18 (1993).
Beighton et al., The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals.Ann. Intern. Med. 84:393-397 (1976).
Beighton et al., The syndromic status of sclerosteosis and van Buchem disease.Clin. Genet. 25: 175-81 (1984).
Bendig et al., Humanization of rodent monoclonal antibodies by CDR grafting.Methods: A companion to Methods of Enzymology. 8: 83-93 (1995).
Bird et al., Single-chain antigen-binding proteins.Science, 242:423-426 (1988).
Black et al., A somatic cell hybrid map of the long are of human chromosome 17, containing the familial breast cancer locus (BRCAI)Am. J. Hum. Genet. 52: 702-10 (1993).
Boden et al., Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6.Endocrinology, 138(7):2820-2828 (1997).
Boerner et al., Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes.J. Immunol., 147:86-95 (1991).
Bonaldo et al., Normalization and subtraction: two approaches to facilitate gen discovery,Genome Res. 6(9): 791-806 (1996).
Bondestam, Ligands & Signaling Components of the Transforming Growth Factor, Helsinki University Biomedical Dissertations (2002).
Bork et al., Go hunting in sequence databases by watch out for the traps.Trends Genet. 12: 4225-7 (1996).
Bost et al., Antibodies against a peptide sequence within the HIV envelope
Latham John
Shi Jiye
Winkler David G.
Kemmerer Elizabeth C.
Marshall & Gerstein & Borun LLP
UCB Manufacturing, Inc.
LandOfFree
Immunogenic peptides derived from sclerostin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides derived from sclerostin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides derived from sclerostin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701607